IA Trial Radar
L'essai clinique NCT07345273 (RADAR) pour Adénocarcinome rectal est pas encore en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Reporting of Tumour Deposits in Colorectal Cancer by Radiology and Pathology (RADAR) 225

Pas encore en recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT07345273 (RADAR) est une étude observationnel pour Adénocarcinome rectal. Son statut actuel est : pas encore en recrutement. Le recrutement est prévu pour commencer le 1 février 2026, avec un objectif de 225 participants. Dirigée par Imperial College, Londres, l'étude devrait être terminée d'ici le 1 mai 2026. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 15 janvier 2026.
Résumé succinct
Recent research shows that tumour deposits-small spots of cancer found near the main bowel tumour-may give doctors important information about how aggressive the cancer is and how likely it is to come back.

Doctors can find tumour deposits either:

  1. When looking at scans before surgery, or
  2. when examining the removed bowel tissue under the microscope after surgery.

In the past, tumour deposits were not always r...

Afficher plus
Description détaillée
Background:

There is increasing evidence that Tumour Deposits (TDs) play an important role in determining prognosis in colorectal cancer patients, both on pathology and on pre-operative imaging (1-2). There is a great variation in their reported prevalence on pathology (1) depending on the staging system and pathology techniques used. Previous work to determine the prevalence of TDs in the UK has relied on the TNM 5...

Afficher plus
Titre officiel

Reporting of Tumour Deposits in Colorectal Cancer by Radiology and Pathology

Pathologies
Adénocarcinome rectal
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'étude
  • RADAR
  • 183491
Numéro NCT
NCT07345273
Date de début (réel)
2026-02
Dernière mise à jour publiée
2026-01-15
Date de fin (estimée)
2026-05
Inscription (estimée)
225
Type d'étude
Observationnel
Statut
Pas encore en recrutement
Mots clés
Rectal Adenocarcinoma
Tumour Deposits
TNM staging
Extramural Venous Invasion
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
TNM5
Patients with rectal cancer diagnosed between 2007-2017 who were staged using TNM5
No Intervention: Observational Cohort
No intervention is to be performed. This is an observational retrospective cohort study only
TNM8
Patients with rectal cancer diagnosed between 2022-2024 who were staged using TNM8
No Intervention: Observational Cohort
No intervention is to be performed. This is an observational retrospective cohort study only
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Frequency of Tumour Deposits
1. The frequency of Tumour Deposits on MRI in the TNM 8 cohort compared to TNM 5 cohort and 2. The frequency of Tumour Deposits on pathology in the TNM 8 cohort compared to TNM 5 cohort
For MRI: MRI reporting within 8 weeks prior to surgery For pathology: Pathology reporting up to 4 weeks after surgery
Critère secondaire d'évaluation
Critères d'évaluationDescription de la mesurePériode
The correlation between reporting of tumour deposits and extramural venous invasion
1. The percentage of patients with extramural venous invasion on MRI among patients with MRI-detected tumour deposits. Measurement tool is standardised colorectal cancer pelvic MRI reporting. 2. The percentage of patients with histopathological extramural venous invasion among patients with histopathologically confirmed tumour deposits. Measurement tool is standardised colorectal cancer histopathology reporting.
For MRI: MRI reporting within 8 weeks prior to surgery For pathology: Pathology reporting up to 4 weeks after surgery
Assistant à la participation
Critères d'éligibilité

Âges éligibles
Enfant, Adulte, Adulte âgé
Âge minimum
16 Years
Sexes éligibles
Tous
  1. Primary adenocarcinoma of the rectum (proven by biopsy)
  2. Undergone surgical resection between 01st January 2007 to 31st December 2017 inclusive for the TNM 5 cohort
  3. Undergone surgical resection between 01st January 2022 to 31st December 2024 inclusive for the TNM 8 cohort

3. Staging with MRI reports are available 4. Post-operative pathology report available 5. Patients aged 16 years and over

  1. Synchronous metastatic tumours
  2. Under the age of 16 years
  3. MRI and/or pathology reports are not available
Imperial College London logoImperial College, Londres
Contact central de l'étude
Contact: Gina Brown, 07917302097, [email protected]
Contact: Harpreet Sekhon, 07923595222, [email protected]
4 Centres de l'étude dans 1 pays

Select Your County

Croydon Health Services NHS Trusts, Croydon, Select Your County, CR7 7YE, United Kingdom
Annabel Shaw, Contact, 07708925886, [email protected]
Annabel Shaw, Investigateur principal
London North West University Healthcare NHS Trust, London, Select Your County, NW10 7NS, United Kingdom
Nicola Hodges, Contact, 07702088521, [email protected]
Nicola Hodges, Investigateur principal
Basingstoke and North Hampshire Hospital, Basingstoke, RG24 9NA, United Kingdom
Amy Lord, Contact, 07841590064, [email protected]
Amy Lord, Investigateur principal
Epsom and St Helier University Hospitals NHS Trust, Surrey Quays, SM5 1AA, United Kingdom
Tou Pin Chang, Contact, [email protected]
Tou Pin Chang, Investigateur principal